Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.
about
PI3K/Akt/mTOR inhibitors in breast cancerPotential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancerOptimal management of hormone receptor positive metastatic breast cancer in 2016Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancersHormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.Pathways and biomarkers in breast cancer: latest evidence.Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast CancerAnalysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.HOXB7 as a promising molecular marker for metastasis in cancers: a meta-analysis.Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.Precision medicine for metastatic breast cancer--limitations and solutions.Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer.Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape.The therapeutic potential of mTOR inhibitors in breast cancer.Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.Down-regulation of hK7 in the sera of breast cancer and benign breast disease patients.Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.The Changing Landscape of Breast Cancer: How Biology Drives Therapy.Activation of phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway and response to everolimus in endocrine receptor-positive metastatic breast cancer - A retrospective pilot analysis and viewpoint.Tumor-biopsy stratification based on mTOR-pathway activity and functional mutations in the upstream genes PIK3CA and PTEN.Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer.
P2860
Q26771394-B175DECC-2B18-42EF-A0EA-AEF038C77545Q26775361-671D038B-25A1-4FBD-AC50-2D3219FA5D0FQ26777683-8B83B2FF-3AD6-41CE-8ED5-200C72A01148Q28081872-0EBB84E2-159F-450F-8362-92FF9500CCB8Q33656801-597CF90E-E6FF-48D5-A47B-6F0C7F2C878BQ36061181-3490C348-5F71-4E9D-9495-DB3DEA7D26CCQ36579447-FBCD178A-061D-4B8F-94E6-59AEFF177FA1Q36804506-4D7A28C7-3734-4ABF-81BE-03DF2AB2B034Q36908034-E9BF68E0-3EE3-4BC7-B674-5C9777D80A8FQ37631514-DCF80E08-6001-4D35-9C98-DFDCA6C697BBQ37691173-B8BE21BC-D999-4620-B274-7FBA787B9BB0Q38502890-F66E770F-48D4-45BA-B9FC-5107D74B6FEBQ38527936-4C8B6BF2-C0A8-49AE-9380-5CAF1B91057DQ38551394-BF6F74C6-A093-4591-AFF8-106B88937201Q38690803-799FFDA4-E7CC-4503-B8BD-DB9F791BA4EBQ38784119-85F71888-423B-4829-B17A-7BDA836A83E4Q38802412-C371CEA6-4023-4206-8399-0D8F8E7D6161Q40202162-7777D3C7-A021-4C75-B5E7-454F79555744Q41094014-E9A96067-A501-4F06-B605-9666AA0E8EB6Q41547803-D2EDD111-B00C-4D94-ACCE-1C0376B5C344Q41747966-FEDBFCFA-FFFD-4BD8-95E6-9500871EED48Q42364826-2DE923B4-DC11-461C-BDE6-D5AD504CF5FCQ46589041-E8D5166F-3F95-426B-9427-DE6C0C390298Q47101508-4DE3D893-4FC8-4675-9310-2B68F1B4E11D
P2860
Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Translational studies within t ...... acy in advanced breast cancer.
@en
Translational studies within t ...... acy in advanced breast cancer.
@nl
type
label
Translational studies within t ...... acy in advanced breast cancer.
@en
Translational studies within t ...... acy in advanced breast cancer.
@nl
prefLabel
Translational studies within t ...... acy in advanced breast cancer.
@en
Translational studies within t ...... acy in advanced breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Translational studies within t ...... acy in advanced breast cancer.
@en
P2093
A Lortholary
A-V Bourcier
E Legouffe
E Pujade-Lauraine
I Treilleux
J-C Eymard
J-M Ferrero
P2860
P304
P356
10.1093/ANNONC/MDU497
P577
2014-10-31T00:00:00Z